Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
RESEARCH ARTICLE

Physician testing for HIV in patients treated with tenofovir disoproxil fumarate and lamivudine monotherapy for hepatitis B virus

Jillian S. Y. Lau A , Dilip Ratnam B C and Ian Woolley A C D
+ Author Affiliations
- Author Affiliations

A Monash Infectious Diseases, Monash Health, Clayton, Vic. 3168, Australia.

B Department of Gastroenterology and Hepatology, Monash Health, Clayton, Vic. 3168, Australia.

C School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic. 3168, Australia.

D Corresponding author. Email: ian.woolley@monash.edu

Sexual Health - https://doi.org/10.1071/SH17045
Submitted: 20 February 2017  Accepted: 5 June 2017   Published online: 13 July 2017

Abstract

Previously we found that local patients were often not tested for HIV prior to commencing nucleoside/nucleotide reverse transcription inhibitor (NRTI) therapy for hepatitis B virus. We performed a national cross-sectional cohort study of physician practices via an online survey. A small majority (23/44; 52%) of participants reported always testing their hepatitis B virus patients for HIV prior to NRTI therapy, and 8/44 (18%) reported testing for HIV the majority of the time. Thirteen (30%) respondents reported testing only if risk factors were present. One physician reported a patient seroconverting to HIV while on TDF monotherapy.


References

[1]  Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available online at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf [verified 28 July 2016].

[2]  Davies O, Alexander H, Robinson N, Pace M, Brady M, Frater J, Fox J. Failure of daily tenofovir to prevent HIV transmission or the establishment of a significant viral reservoir despite continued antiretroviral therapy. J Int AIDS Soc 2014; 17 19731
Failure of daily tenofovir to prevent HIV transmission or the establishment of a significant viral reservoir despite continued antiretroviral therapy.CrossRef |

[3]  Lehman DA, Baeten JM, McCoy CO, Weis JF, Peterson D, Mbara G, et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent pre-exposure prophylaxis. J Infect Dis 2015; 211 1211–8.
Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent pre-exposure prophylaxis.CrossRef | 1:CAS:528:DC%2BC28XitFCjsb7N&md5=c94ea8e38fcbc274f9cc383fca561e99CAS |

[4]  Deshpande S, Ko T, Roberts E, Lau JSY, Horne K, Williams J, Kiss C, Ratnam D, Woolley I. Tenofovir therapy for hepatitis B may be commonly prescribed without HIV testing. J Acquir Immune Defic Syndr 2016; 71 e53–4.
Tenofovir therapy for hepatitis B may be commonly prescribed without HIV testing.CrossRef |

[5]  McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, Xing S, Bhat S, Hale B, Hegarty R, Chong CR, Liu JO, Siliciano RF, Thio CL. The HBV drug entecavir — effects on HIV-1 replication and resistance. N Engl J Med 2007; 356 2614–21.
| 1:CAS:528:DC%2BD2sXmslKjs7o%3D&md5=2c1145dcfee1c5836db85a1652a39208CAS |

[6]  Guidance: HIV in indicator conditions. HIV in Europe – working together for optimal testing and earlier care. Available online at: http://newsite.hiveurope.eu/Finalised-Projects/Guidance-HIV-Indicator-Conditions [verified 30 July 2016].

[7]  European Association for the Study of the Liver. Chronic hepatitis B infection clinical practice guidelines. Available online at: http://www.easl.eu/research/ our-contributions/clinical-practice-guidelines/ detail/management-of-chronic-hepatitis-b-virus- infection/report/4 [verified 31 August 2015].

[8]  GILEAD. Tenofovir disoproxil fumarate product information. Available online at: http://www.gilead.com/~/media/files/pdfs/medicines/liver-disease/viread/viread_pi.pdf?la=en [verified 30 July 2016].

[9]  Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available online at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf [verified 28 July 2016].

[10]  World Health Organization. First-line ART for adults. Available online at: http://www.who.int/hiv/pub/guidelines/arv2013/art/artadults/en/ [verified 1 October 2016].

[11]  Woolley I. Isn’t it time to talk about antiretroviral stewardship? J Chemother 2016; 28 352–4.
Isn’t it time to talk about antiretroviral stewardship?CrossRef |



Export Citation